Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie CEO defends Pharmacyclics deal to skeptical investors

[Reuters] – AbbVie Inc chief Richard Gonzalez fought two other drugmakers to “the bitter end” to buy Pharmacyclics Inc for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie CEO defends Pharmacyclics deal to skeptical investors Similar Articles: Market Update (NYSE:ABBV): AbbVie cools on $55 bln Shire deal after U.S. tax changes Company Update: AbbVie Inc (NYSE:ABBV) – EU to decide on $52 bln AbbVie, Shire deal by Oct. 16 Market Update (NYSE:ABBV): AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says